Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
While Semaglutide (Ozempic, Wegovy) targets one receptor and Tirzepatide (Mounjaro, Zepbound) targets two, Retatrutide activates three distinct metabolic receptors simultaneously
While AOD-9604 is not FDA-approved as a prescription drug, it has received GRAS (Generally Recognized as Safe) status, indicating low toxicity and a good safety profile
Pharmacokinetics indicate moderate half-lives with effects observed in animal models for days post administration
Cagrilintide acts via amylin and calcitonin receptors, while semaglutide, tirzepatide, and retatrutide target incretin (GLP-1/GIP) receptors
US$ 29.26
US$ 26.46
US$ 24.45
.jpg)
US$ 22.83
US$ 25.96
US$ 26.48
/assets/production/practices/8374cadb2253e5496cfee3ef82ab5175a5e6343b/images/2820182.png)
US$ 21.61
US$ 26.18
